One-year data from the REMAIN-1 midpoint cohort show Revita enables durable weight maintenance after GLP-1 discontinuation, with up to 84% of weight loss retained and a favorable safety profile. Dose optimization enhances efficacy, and strong patient demand is anticipated.

Based on

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.